Biotechnology
Gilead Sciences, the Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP), and the World Hepatitis Alliance (WHA) Collaborate to Support Elimination of Hepatitis by 2030
* Today, an Estimated 257 Million People Live With Hepatitis B Globally. The World Health Organization Has Categorized Viral Hepatitis as a Public Health Threat and Has Set Targets for Elimination by 2030. * Despite National Immunization Programs Being Implemented in the 1980s, More Than 50% ...
2021-11-23 11:00
1571
EZZ accelerates genomic health focus with launch of two new biotic products
SYDNEY, Nov. 23, 2021 /PRNewswire/ -- EZZ Life Science Holdings Limited (ASX: EZZ),an Australian genomic life science company with a mission to improve quality of life and human health, is pleased to have added two new consumer health products to its range, to be sold in pharmacies acrossAustrali...
2021-11-23 04:00
1837
Arctic Vision Announces First Patient Dosed in Phase III Study of ARVN001 for Treatment of Macular Edema Associated with Uveitis (UME)
* First-in-class SCS Microinjection therapy * First clinical registration study and potentially the first approved drug in China targeting macular edema associated with uveitis * U.S. FDA approved for treatment of macular edema associated with uveitis SHANGHAI, Nov. 22, 2021 /PRNewswire/ -- A...
2021-11-22 23:17
1496
Getinge accelerates growth and productivity to reach new financial targets
GOTHENBURG, Sweden, Nov. 22, 2021 /PRNewswire/ -- "Getinge's new financial targets for 2022-2025, an annual organic net sales growth of 4-6% and adjusted EPS growth of above 10% on average throughout the period, is well in line with our strategy and ambitions", says Mattias Perjos, President & CE...
2021-11-22 21:50
1612
Ascentage Pharma's Olverembatinib Granted Orphan Designation by the European Commission for the Treatment of Chronic Myeloid Leukemia
SUZHOU, China, and ROCKVILLE, MD., Nov. 22, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the European Commission (EC) has granted the...
2021-11-22 21:24
1798
Alterity Therapeutics to Participate in Two Upcoming Investor Conferences
MELBOURNE, Australia and SAN FRANCISCO, Nov. 22, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced thatDavid Stamler, M.D...
2021-11-22 20:50
1815
Baidu Enters Into License Agreement With Sanofi to Enable Next-Generation mRNA Therapeutics and Vaccines
BEIJING, Nov. 22, 2021 /PRNewswire/ -- Baidu, Inc. (NASDAQ:BIDU and HKEX:9888), a leading AI company with strong Internet foundation, and Sanofi, a leading biopharmaceutical company focused on human health, have entered into an agreement to integrate Baidu's messenger ribonucleic acid (mRNA) desi...
2021-11-22 20:00
1990
CARsgen Receives CTA Authorization from Health Canada for CLDN18.2-targeted CAR T-cell Product CT041
SHANGHAI, Nov. 22, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, today announced that the Company has received a No Objection Letter from...
2021-11-22 20:00
1973
Breakthrough Chemotherapy Heart Protection Discovery for Australian Biotech
* Race Oncology's drug Zantrene shown to protect human heart muscle cells from anthracycline-induced chemotherapy death. Anthracycline's are the most used and effective anti-cancer drugs, yet they can cause serious heart damage. * The preclinical research also demonstrated Zantrene's ability t...
2021-11-22 09:24
2403
DSM recognized for advancing sustainable food commitments and novel science-based solutions across Asia Pacific
SINGAPORE, Nov. 22, 2021 /PRNewswire/ -- Royal DSM, a global purpose-led
science-based company active in Health, Nutrition and Bioscience has been
awarded 'Asia's Most Sustainable Company of the Year' by Asia Corporate
Excellence & Sustainability (ACES) Awards.
2021-11-22 09:00
2323
Innovent Announces Inclusion of the Company's Stock (01801.HK) in the Hang Seng China Enterprises Index
SAN FRANCISCO and SUZHOU, China, Nov. 22, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2021-11-22 08:00
3464
CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China
SUZHOU, China, Nov. 21, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, and Jiangsu Hengrui Pharmaceuticals ("Hengru...
2021-11-21 17:09
3242
CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China
SUZHOU, China, Nov. 21, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, and Jiangsu Hengrui Pharmaceuticals ("Hengru...
2021-11-21 17:02
2588
US FDA Grants Breakthrough Designation for Early-Stage Breast Cancer Detection Blood Test Developed by Datar Cancer Genetics
LONDON, Nov. 20, 2021 /PRNewswire/ -- Datar Cancer Genetics, a leading cancer research company focussed on early detection of cancers today announced that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its blood test to detect early-stage Breast Cancer...
2021-11-20 08:00
4471
Kangtai Adenovirus Vector COVID-19 Vaccine (KCONECAVAC) Exported for the First Time
SHENZHEN, China, Nov. 19, 2021 /PRNewswire/ -- At 3 a.m. on November 19, the first batch of more than 4 million doses of adenovirus vector COVID-19 vaccines produced by Shenzhen Kangtai Biological Products Co., Ltd. will depart from Shenzhen Bao'an International Airport and will arrive in Jakarta...
2021-11-19 18:52
1693
Vazyme Attends Medica 2021 in Germany to Accelerate Its Global Market Expansion
DUSSELDORF, Germany, Nov. 19, 2021 /PRNewswire/ -- Chinese biotechnology company Vazyme (688105.SH) recently attended Medica 2021 in Germany—one of the world's largest events for the medical sector—to accelerate the expansion of its international business. At the event, Vazyme introduced its newe...
2021-11-19 15:18
2995
ASRA 2021 | Cali Biosciences Presents Phase IIa Clinical Data on CPL-01, a Long-Acting Ropivacaine
SAN DIEGO, Nov. 19, 2021 /PRNewswire/ -- Cali Biosciences, a global biopharmaceutical company focused on the research and development of innovative drugs, presented Phase IIa clinical data today on its perioperative long-acting ropivacaine, CPL- 01, at the 20th Annual American Society of Regional...
2021-11-19 13:14
1239
Treating Patients Beyond Borders - Antengene Successfully Hosted Its First R&D Day
- Highlighted R&D Strategy and Broad Pipeline of 15 Programs including 10 with Worldwide Rights - ATG-010's First Approval in Asia transforms Antengene into a Commercial Entity, 10 Studies in ATG-010 being Conducted in Mainland China - Exciting ATG-008 (mTORC1/2 inhibitor) Signal, ATG-017 (ER...
2021-11-19 13:00
3395
Antengene Announces IND Approval in China for a Phase I/II Study of Selinexor (ATG-010) in Patients with Non-Hodgkin Lymphoma
SHANGHAI and Hong Kong, Nov. 19, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and onco...
2021-11-19 08:30
2751
Tavotek Biotherapeutics Announces Completion of Round B Financing with $35 Million
LOWER GWYNEDD, Penn., Nov. 18, 2021 /PRNewswire/ -- Tavotek Biotherapeutics, a fast-growing biotech company, announces it has raised $35M in Round B financing. CS Capital, a leading private equity fund manager in China, led this finance round followed by Fontus Capital. This round of financing wi...
2021-11-19 08:00
1539
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8546
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7700